Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Presentation on ‘Adapting during crisis’
Manchester, UK – 7 April 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that Hayden Jeffreys, Chief Operating Officer of Yourgene Health, will be presenting at 4pm today at the virtual webinar event ‘Adapting during crisis’ hosted by Bruntwood Sci-Tech.
Bruntwood Sci-Tech will be joined by its customers from across Manchester and Innovation Birmingham who have adapted their business due to COVID-19. Hayden Jeffreys will talk about how the Company has modified its working practices to adapt to social distancing, whilst maintaining key medical diagnostics supply to the NHS and to its global networks. Additionally, the webinar will cover how the Company has utilised Yourgene’s state-of-the-art facilities at Citylabs, part of the Bruntwood Sci-Tech space, to support the contract manufacture of COVID-19 diagnostic tests.
The virtual event is free, but places are limited, so please register here:
https://www.eventbrite.co.uk/e/bruntwood-scitech-adapting-during-crisis-online-tickets-101710316294
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 |
Stifel Nicolaus Europe Limited (Sole Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison | Tel: +44 (0)20 7710 7600 |
Walbrook PR Ltd (Media and Investor Relations) Paul McManus / Lianne Cawthorne | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Mob: 07980 541 893 Mob: 07584 391 303 |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
